#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At